uniQure N.V. Company Profile (NASDAQ:QURE)

About uniQure N.V. (NASDAQ:QURE)

uniQure N.V. logouniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company's product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington's disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington's disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:QURE
  • CUSIP: N/A
  • Web: www.uniqure.com
Capitalization:
  • Market Cap: $208.94 million
  • Outstanding Shares: 25,443,000
Average Prices:
  • 50 Day Moving Avg: $5.94
  • 200 Day Moving Avg: $5.80
  • 52 Week Range: $4.72 - $9.72
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.73
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $24.12 million
  • Price / Sales: 8.64
  • Book Value: $1.80 per share
  • Price / Book: 4.55
Profitability:
  • EBIDTA: ($66,070,000.00)
  • Net Margins: -223.38%
  • Return on Equity: -103.26%
  • Return on Assets: -36.63%
Debt:
  • Debt-to-Equity Ratio: 0.39%
  • Current Ratio: 6.04%
  • Quick Ratio: 6.04%
Misc:
  • Average Volume: 127,652 shs.
  • Beta: 0.32
  • Short Ratio: 6.36
 
Frequently Asked Questions for uniQure N.V. (NASDAQ:QURE)

What is uniQure N.V.'s stock symbol?

uniQure N.V. trades on the NASDAQ under the ticker symbol "QURE."

How were uniQure N.V.'s earnings last quarter?

uniQure N.V. (NASDAQ:QURE) released its earnings results on Tuesday, May, 9th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.16. The firm earned $3.32 million during the quarter, compared to analyst estimates of $4.20 million. uniQure N.V. had a negative net margin of 223.38% and a negative return on equity of 103.26%. View uniQure N.V.'s Earnings History.

Where is uniQure N.V.'s stock going? Where will uniQure N.V.'s stock price be in 2017?

8 equities research analysts have issued 12 month target prices for uniQure N.V.'s stock. Their predictions range from $8.00 to $27.00. On average, they expect uniQure N.V.'s stock price to reach $16.57 in the next year. View Analyst Ratings for uniQure N.V..

What are analysts saying about uniQure N.V. stock?

Here are some recent quotes from research analysts about uniQure N.V. stock:

  • 1. Cowen and Company analysts commented, "QURE reported 1Q17 financials and presented multiple updates at ASGCT recently." (5/24/2017)
  • 2. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (5/17/2017)

Who are some of uniQure N.V.'s key competitors?

Who owns uniQure N.V. stock?

uniQure N.V.'s stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Creative Planning (0.12%). View Institutional Ownership Trends for uniQure N.V..

How do I buy uniQure N.V. stock?

Shares of uniQure N.V. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is uniQure N.V.'s stock price today?

One share of uniQure N.V. stock can currently be purchased for approximately $8.19.


MarketBeat Community Rating for uniQure N.V. (NASDAQ QURE)
Community Ranking:  4.1 out of 5 (   )
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  379
MarketBeat's community ratings are surveys of what our community members think about uniQure N.V. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for uniQure N.V. (NASDAQ:QURE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $16.57 (102.34% upside)

Analysts' Ratings History for uniQure N.V. (NASDAQ:QURE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/30/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$17.00LowView Rating Details
5/24/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingHold$8.00LowView Rating Details
1/30/2017Chardan CapitalReiterated RatingPositive$12.00N/AView Rating Details
12/2/2016Leerink SwannReiterated RatingOutperformN/AView Rating Details
12/6/2016WallachBeth CapitalLower Price TargetBuy$27.00 -> $15.00N/AView Rating Details
11/15/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
8/4/2016HC WainwrightInitiated CoverageBuy$21.00N/AView Rating Details
1/8/2016Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
1/8/2016Roth CapitalReiterated RatingBuy$37.00N/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for uniQure N.V. (NASDAQ:QURE)
Earnings by Quarter for uniQure N.V. (NASDAQ:QURE)
Earnings History by Quarter for uniQure N.V. (NASDAQ QURE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/20173/31/2017($0.64)($0.80)$4.20 million$3.32 millionViewN/AView Earnings Details
5/31/2016Q1($0.82)($0.93)$2.94 million$4.30 millionViewN/AView Earnings Details
4/4/2016Q415($0.60)($0.58)$2.78 million$6.78 millionViewN/AView Earnings Details
11/30/2015Q315($0.64)($1.14)$7.76 million$3.50 millionViewListenView Earnings Details
8/27/2015Q215($0.56)($0.98)$31.18 million$1.79 millionViewN/AView Earnings Details
6/11/2015Q1($0.82)($0.69)$9.50 million$1.17 millionViewN/AView Earnings Details
4/6/2015($0.62)($0.77)$1.38 million$1.61 millionViewN/AView Earnings Details
12/1/2014($0.53)($0.61)$2.00 million$1.30 millionViewN/AView Earnings Details
9/2/2014Q214($0.55)($1.35)$1.40 million$1.37 millionViewN/AView Earnings Details
6/6/2014($0.45)($0.52)$0.84 million$1.59 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for uniQure N.V. (NASDAQ:QURE)
2017 EPS Consensus Estimate: ($2.73)
2018 EPS Consensus Estimate: ($2.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.71)($0.71)($0.71)
Q2 20172($0.81)($0.71)($0.76)
Q3 20171($0.77)($0.77)($0.77)
Q4 20171($0.49)($0.49)($0.49)
Q1 20181($0.73)($0.73)($0.73)
Q2 20181($0.67)($0.67)($0.67)
Q3 20181($0.69)($0.69)($0.69)
Q4 20181($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for uniQure N.V. (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for uniQure N.V. (NASDAQ:QURE)
Insider Ownership Percentage: 0.64%
Institutional Ownership Percentage: 30.49%
Insider Trades by Quarter for uniQure N.V. (NASDAQ:QURE)
Institutional Ownership by Quarter for uniQure N.V. (NASDAQ:QURE)
Insider Trades by Quarter for uniQure N.V. (NASDAQ:QURE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/29/2017Harald PetryInsiderSell49,300$6.02$296,786.00View SEC Filing  
6/27/2017Harald PetryInsiderSell65,930$6.01$396,239.30View SEC Filing  
6/26/2017Harald PetryInsiderSell58,075$6.01$349,030.75View SEC Filing  
6/22/2017Harald PetryInsiderSell155$6.00$930.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for uniQure N.V. (NASDAQ:QURE)
Latest Headlines for uniQure N.V. (NASDAQ:QURE)
Source:
DateHeadline
globenewswire.com logouniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene ... - GlobeNewswire (press release)
globenewswire.com - July 22 at 8:03 AM
nasdaq.com logouniQure NV (QURE) Shows Strength: Stock Moves 9.1% Higher - Nasdaq
www.nasdaq.com - July 22 at 8:03 AM
finance.yahoo.com logouniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program
finance.yahoo.com - July 22 at 8:03 AM
globenewswire.com logouniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell ... - GlobeNewswire (press release)
globenewswire.com - July 19 at 6:25 AM
finance.yahoo.com logouniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell-Based AAV Manufacturing
finance.yahoo.com - July 18 at 7:45 AM
americanbankingnews.com logo$2.92 Million in Sales Expected for uniQure N.V. (QURE) This Quarter
www.americanbankingnews.com - July 15 at 7:34 AM
americanbankingnews.com logo-$0.86 EPS Expected for uniQure N.V. (QURE) This Quarter
www.americanbankingnews.com - July 13 at 10:18 PM
streetinsider.com logouniQure (QURE) Reports Updated Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
www.streetinsider.com - July 11 at 6:57 AM
finance.yahoo.com logouniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B
finance.yahoo.com - July 11 at 6:57 AM
finance.yahoo.com logouniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies
finance.yahoo.com - July 11 at 6:57 AM
americanbankingnews.com logouniQure N.V. (QURE) Given "Outperform" Rating at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - June 30 at 7:46 PM
americanbankingnews.com logouniQure N.V. (QURE) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 30 at 12:44 PM
americanbankingnews.com logoHarald Petry Sells 49,300 Shares of uniQure N.V. (QURE) Stock
www.americanbankingnews.com - June 29 at 7:47 PM
americanbankingnews.com logoHarald Petry Sells 58,075 Shares of uniQure N.V. (QURE) Stock
www.americanbankingnews.com - June 28 at 10:23 PM
americanbankingnews.com logouniQure N.V. (QURE) Insider Harald Petry Sells 65,930 Shares
www.americanbankingnews.com - June 28 at 7:24 PM
streetinsider.com logouniQure (QURE) Reports Presentations at ISTH
www.streetinsider.com - June 23 at 8:16 PM
globenewswire.com logouniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis ... - GlobeNewswire (press release)
globenewswire.com - June 23 at 9:24 AM
americanbankingnews.com logoComparing uniQure N.V. (QURE) & BIOVERATIV INC (BIVV)
www.americanbankingnews.com - June 20 at 12:30 PM
americanbankingnews.com logoZacks: Brokerages Anticipate uniQure N.V. (QURE) Will Announce Earnings of -$0.86 Per Share
www.americanbankingnews.com - June 19 at 10:26 PM
nasdaq.com logouniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based ... - Nasdaq
www.nasdaq.com - June 16 at 8:29 PM
streetinsider.com logoForm 8-K uniQure NV For: Jun 14 - StreetInsider.com
www.streetinsider.com - June 16 at 3:27 PM
finance.yahoo.com logouniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies
finance.yahoo.com - June 15 at 4:19 PM
seekingalpha.com logoUniqure N.V. (QURE) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 13 at 10:11 AM
globenewswire.com logouniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer - GlobeNewswire (press release)
globenewswire.com - June 6 at 8:32 PM
finance.yahoo.com logouniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer
finance.yahoo.com - June 6 at 8:32 PM
americanbankingnews.com logoUniqure NV (QURE) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 5 at 11:11 AM
americanbankingnews.com logoUniqure NV (QURE) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - June 3 at 2:02 PM
finance.yahoo.com logouniQure NV :QURE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 10:22 PM
nasdaq.com logouniQure Announces Company Presentation at Jefferies Healthcare ... - Nasdaq
www.nasdaq.com - June 1 at 8:57 PM
globenewswire.com logouniQure Announces Company Presentation at Jefferies Healthcare ... - GlobeNewswire (press release)
globenewswire.com - June 1 at 8:34 AM
finance.yahoo.com logouniQure Announces Company Presentation at Jefferies Healthcare Conference
finance.yahoo.com - June 1 at 8:34 AM
bizjournals.com logoHemophilia A Therapeutics Pipeline (Hematological Disorders) Review H1 2017 Market Report
www.bizjournals.com - May 31 at 7:31 PM
americanbankingnews.com logo$2.92 Million in Sales Expected for Uniqure NV (QURE) This Quarter
www.americanbankingnews.com - May 26 at 1:52 PM
americanbankingnews.com logoCowen and Company Reaffirms "Buy" Rating for Uniqure NV (QURE)
www.americanbankingnews.com - May 24 at 4:32 PM
americanbankingnews.com logoShort Interest in Uniqure NV (QURE) Drops By 1.7%
www.americanbankingnews.com - May 22 at 9:16 PM
americanbankingnews.com logoFY2017 EPS Estimates for Uniqure NV (QURE) Decreased by Analyst
www.americanbankingnews.com - May 18 at 10:38 AM
americanbankingnews.com logoUniqure NV (QURE) PT Set at $17.00 by Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 17 at 7:10 PM
americanbankingnews.com logoUniqure NV (QURE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 17 at 7:48 AM
americanbankingnews.com logoUniqure NV (QURE) Forecasted to Earn Q2 2017 Earnings of ($0.81) Per Share
www.americanbankingnews.com - May 17 at 7:42 AM
globenewswire.com logouniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of ... - GlobeNewswire (press release)
globenewswire.com - May 12 at 8:04 AM
streetinsider.com logouniQure (QURE) Presents Data on Successful Readministration of Gene Therapy in Non-Human Primates - StreetInsider.com
www.streetinsider.com - May 12 at 8:04 AM
finance.yahoo.com logouniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates
finance.yahoo.com - May 11 at 8:22 AM
americanbankingnews.com logoUniqure NV (QURE) Posts Earnings Results, Misses Expectations By $0.16 EPS
www.americanbankingnews.com - May 10 at 4:56 PM
streetinsider.com logoForm 8-K uniQure NV For: May 09 - StreetInsider.com
www.streetinsider.com - May 10 at 11:20 AM
reuters.com logoBRIEF-Uniqure NV Q1 loss per share $0.80 - Reuters
www.reuters.com - May 10 at 11:20 AM
finance.yahoo.com logouniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates
finance.yahoo.com - May 10 at 11:20 AM
cnbc.com logoUniQure reports 1Q loss
www.cnbc.com - May 9 at 10:53 AM
reuters.com logoBRIEF-Uniqure NV Q1 loss per share $0.80
www.reuters.com - May 9 at 10:53 AM
finance.yahoo.com logouniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress
finance.yahoo.com - May 9 at 10:53 AM
americanbankingnews.com logoUniqure NV (QURE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 9 at 8:46 AM

Social

Chart

uniQure N.V. (QURE) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff